- Home
- AIM vs NURO Comparison
AIM vs NURO Comparison
Compare AIM & NURO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- NURO
- Stock Information
- Founded
- AIM 1966
- NURO 1996
- Country
- AIM United States
- NURO United States
- Employees
- AIM N/A
- NURO N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- NURO Medical/Dental Instruments
- Sector
- AIM Health Care
- NURO Health Care
- Exchange
- AIM Nasdaq
- NURO Nasdaq
- Market Cap
- AIM 9.8M
- NURO 8.2M
- IPO Year
- AIM N/A
- NURO N/A
- Fundamental
- Price
- AIM $0.14
- NURO $4.39
- Analyst Decision
- AIM Strong Buy
- NURO
- Analyst Count
- AIM 2
- NURO 0
- Target Price
- AIM $2.75
- NURO N/A
- AVG Volume (30 Days)
- AIM 1.5M
- NURO 15.9K
- Earning Date
- AIM 04-01-2025
- NURO 03-04-2025
- Dividend Yield
- AIM N/A
- NURO N/A
- EPS Growth
- AIM N/A
- NURO N/A
- EPS
- AIM N/A
- NURO N/A
- Revenue
- AIM $190,000.00
- NURO $3,767,764.00
- Revenue This Year
- AIM N/A
- NURO N/A
- Revenue Next Year
- AIM $1,693.10
- NURO N/A
- P/E Ratio
- AIM N/A
- NURO N/A
- Revenue Growth
- AIM N/A
- NURO N/A
- 52 Week Low
- AIM $0.12
- NURO $2.66
- 52 Week High
- AIM $0.62
- NURO $4.73
- Technical
- Relative Strength Index (RSI)
- AIM 36.62
- NURO 63.96
- Support Level
- AIM $0.12
- NURO $4.35
- Resistance Level
- AIM $0.21
- NURO $4.45
- Average True Range (ATR)
- AIM 0.02
- NURO 0.06
- MACD
- AIM -0.00
- NURO -0.00
- Stochastic Oscillator
- AIM 22.88
- NURO 60.39
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About NURO NeuroMetrix Inc.
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.